Searchable abstracts of presentations at key conferences in endocrinology

ea0022p390 | Endocrine tumours &amp; neoplasia (<emphasis role="italic">Generously supported by Novartis</emphasis>) | ECE2010

Sex hormone-binding globulin (SHBG) gene pentanucleotide TAAAA repeat and D327N polymorphism in breast cancer: link to estrogen sensitivity

Piccioni Claudia , Catalano Maria Graziella , Boccuzzi Giuseppe , Fortunati Nicoletta

Sex hormone-binding globulin (SHBG) is characterized by the unique ability of regulating estrogen free fraction and cross-talking with estradiol pathways in breast cancer cells, therefore reducing breast cancer cell growth and proliferation. In addition, the presence of the D327N (Asp327Asn, rs6259) single nucleotide polymorphism (SNP) of SHBG exon 8 confers a protective role to SHBG in breast cancer. Another polymorphism that has been receiving quite a lot of at...

ea0081p127 | Endocrine-Related Cancer | ECE2022

Role of DKK1 in growth and migration of prostate cancer cells

Rinella Letizia , Compagno Mara , Fiorentino Gloria , Fortunati Nicoletta , Arvat Emanuela , Catalano Maria Graziella

Androgen deprivation therapy is the choice treatment of metastatic prostatic tumors. Unfortunately, very often, resistance occurs and chemotherapy is needed. Results are however disappointing with frequent side effects. Therefore, new therapeutic approaches for metastatic and advanced prostate cancer are necessary. DKK1, an inhibitor of the Wnt signaling pathway, is increased in different types of cancer. In prostate cancer patients with bone metastases, an increase of DKK1 is...

ea0016oc6.9 | Metabolism and cardiovascular | ECE2008

The histone deacetylase inhibitor valproic acid (VPA) confers an estrogen-sensitive ‘phenotype’ to estrogen receptor-negative breast cancer cells MDA-MB 231

Fortunati Nicoletta , Bertino Silvia , Costantino Lucia , Catalano Maria Graziella , Boccuzzi Giuseppe

Breast cancer cells may present a number of resistance mechanisms to conventional therapy, and therefore new treatments are under evaluation. The histone deacetylase inhibitor (HDI) valproic acid (VPA) is of particular interest, since having been used for a long time in neurological patients its side-effects and tolerability are well known. We have recently demonstrated that VPA is a powerful antiproliferative agent in estrogen-sensitive breast cancer cells. Unfortunately, its...

ea0016p288 | Endocrine tumours | ECE2008

Effects of the potent deacetylase inhibitor Panobinostat (LBH589) against poorly differentiated and anaplastic thyroid cancer cells

Catalano Maria Graziella , Pugliese Mariateresa , Bosco Ornella , Fortunati Nicoletta , Boccuzzi Giuseppe

Poorly differentiated and anaplastic thyroid carcinomas are aggressive human cancers that are resistant to conventional therapy. DAC inhibitors (DACi) are a promising class of drugs, acting as anti-proliferative agents by inducing apoptosis and cell cycle arrest.Panobinostat (LBH589) is a potent DACi belonging to a structurally novel cinnamic hydroxamic acid class of compounds, able to inhibit the activity of different isoforms of HDACs (HDAC 1, 3–6...

ea0016p655 | Signal transduction | ECE2008

D327N SHBG is more effective than wild-type as modulator of estradiol signalling in breast cancer cells

Costantino Lucia , Catalano Maria Graziella , Frairia Roberto , Boccuzzi Giuseppe , Fortunati Nicoletta

Sex hormone-binding globulin (SHBG), the specific plasma carrier for sex steroids, regulates hormone bioavailable fraction and estrogen signalling system in breast cancer cells. A common single nucleotide polymorphism in the human SHBG gene results in an amino acid substitution (Asp327Asn), which introduces an additional N-glycosylation site that has been associated with reduced breast cancer risk in postmenopausal women. Since wild-type SHBG was demonstrated to interfe...

ea0022p767 | Thyroid | ECE2010

Panobinostat restores iodine uptake in primary cultures of undifferentiated thyroid tumours

Catalano Maria Graziella , Pugliese Mariateresa , Germano Antonina , Poli Roberta , Palestini Nicola , Mainini Franco , Fortunati Nicoletta , Boccuzzi Giuseppe

A functional sodium iodide symporter (NIS) is essential for radioiodine treatment of thyroid cancer. Unfortunately, most of de-differentiated tumours as well as anaplastic thyroid cancers loss the ability to concentrate iodine. Loss of NIS expression usually depends on epigenetic modifications, suggesting the use of epigenetic drugs as promising tools for re-differentiation. Panobinostat (LBH589) is a novel deacetylase inhibitor, acting at nanomolar concentrations, currently i...